Indolent Non-Hodgkin Lymphoma Clinical Trial
Official title:
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04883437 -
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
|
Phase 2 | |
Completed |
NCT04038359 -
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT04136756 -
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT00075478 -
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 3 | |
Completed |
NCT02242045 -
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
|
Phase 1 | |
Completed |
NCT01231412 -
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
|
Phase 3 | |
Active, not recruiting |
NCT02566304 -
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Recruiting |
NCT04223765 -
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
|
Phase 1 | |
Active, not recruiting |
NCT03035331 -
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05876923 -
The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
|
N/A | |
Completed |
NCT00723099 -
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03105336 -
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
|
Phase 2 | |
Withdrawn |
NCT04372641 -
Testing the Safety of CB-5339 in Patients With Cancer
|
Phase 1 | |
Completed |
NCT01882803 -
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04323956 -
Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT04464200 -
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
|
Phase 1 | |
Recruiting |
NCT05783596 -
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03749018 -
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03884998 -
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
|
Phase 1 | |
Terminated |
NCT01944943 -
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 2 |